Tom DeBourcy

My question is just on the Diagnosis and Genomics organic growth. I know you have more difficult comps in the second half of the year

Just had a question related to your kind of directional guidance on Q2, and I guess kind of sequentially flat

would you expect that to be incrementally better versus last year?

how you think about that business? I know you have the secrete platform and how you think about, I guess, adding to that portfolio

refilling that demand. I wanted to see the opportunities you are seeing there,

are most of the products in the portfolio validated across either multiple facilities and/or multiple geographies

your ability to capitalize on that opportunity and actually, you know, fill that that supply